About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed

Sample Content 

My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

Journal of Ocular Pharmacology and Therapeutics

Editor: W. Daniel Stamer, PhD

ISSN: 1080-7683 • 10 Issues Annually • Online ISSN: 1557-7732

Current Volume: 30

Latest Impact Factor* is 1.420

*2013 Journal Citation Reports® published by Thomson Reuters, 2014

A dynamic new author services platform
to share, measure, and enhance the impact of your research
Complimentary one-year membership with submission to this journal

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    The Journal of Ocular Pharmacology and Therapeutics (JOPT) is a peer-reviewed journal published 10 times a year.  It includes research on all aspects of drug activity that pertain to preventing or controlling diseases/conditions of the eye. Before acceptance, your paper will be anonymously reviewed by two or more competent peers.


    Sheryl Nale
    Editorial Coordinator

    Mary Ann Liebert, Inc. Submission Benefits Package

    Your submission to Journal of Ocular Pharmacology and Therapeutics (JOPT) provides you with robust tools and support to ensure maximum impact and readership for your work. By submitting your manuscript, you’ll receive:

    • Complimentary 12-month AuthorCite® membership
      Exclusively licensed by Mary Ann Liebert, Inc., AuthorCite® delivers a 360-degree view of your article from submission to publication to market impact. With an AuthorCite® membership, you’ll receive end-to-end manuscript submission tracking, a custom online microsite to promote you and your research, a professional suite of metrics and analytics to measure the impact of your article, 30-day OpenLink™ article sharing, and much more.
    • Rapid, rigorous peer-review and editorial attention
    • Immediate deposit to PubMed and other indexing services upon online publication
    • Exposure to thousands of thought-leaders in your field, maximizing readers, citations, and downloads
    • Fast Track online-ahead-of-print publication
    • Global availability in over 170 countries
    • Open Access publication options


    Submitting your manuscript to Journal of Ocular Pharmacology and Therapeutics (JOPT) delivers a comprehensive benefits program that ensures high-quality review of your research and maximum impact for your work. This includes a one-year membership to AuthorCite™, a robust author services platform for increasing the visibility of your research, and includes the ability to freely share your article for 30 daysJournal of Ocular Pharmacology and Therapeutics (JOPT) carries a manuscript processing charge* of $75 USD upon submission of each new manuscript.

    Upon payment, you will be provided a Manuscript Submission Code, and will be prompted to enter this information when uploading your files to our peer-review system.  Please note:  Securing a token does not automatically create an account in our peer-review system. If you do not already have an account, you will be asked to create one before you can begin your submission.

    Submissions do not need to be completed at once. Submitting authors/agents may begin the submission process, save their work, and return to the site to complete the upload(s) at a later time. There is no limit on the number of times one can save their work and subsequently resume the submission. Doing so will not incur additional charges.

    Click here to submit your paper via our fast and user-friendly electronic submission system.


    Processing charges and submission codes are NOT required for revisions to previously submitted papers. To upload a revision of a paper, the submitting author should log in to their Author Center at http://mc.manuscriptcentral.com/ocular click on “Revised Manuscripts in Draft.” The paper will appear in this area, and the submitting author will be able to upload revised files without paying any charges or entering a submission code.

    Please be sure to follow the Instructions for Authors below on Manuscript Preparation.  Authors whose submissions do not comply with the Instructions for Authors will have their papers un-submitted so that the file(s) may be adjusted accordingly. Directions regarding the necessary corrective actions will be provided in an email to the corresponding author at the time the paper is un-submitted. The submitting author/agent will then be provided the opportunity to re-upload the corrected file(s). If a paper is un-submitted, the paper will reside in the corresponding author’s “Author Center” as a draft, and the submitting author/agent will be able to make the necessary adjustments and re-upload the paper without incurring another manuscript processing charge. 

    *The manuscript processing charge is independent of editorial decision and is non-refundable.


    Instructions for Authors

    Types of JOPT Communications

    1. Original Articles:  Original Research Articles describing the results of experimental studies that address fundamental issues on therapies directed toward eye disease/disorders constitutes the majority of communications published in JOPT.  Detailed instructions for formatting original research articles are provided below under the subheading “CORRESPONDING AUTHOR RESPONSIBILITIES”.

    2. Letters to the Editor: Letters to the Editor provide substantive comment(s) on a publication in JOPT or an ocular pharmacology/therapeutic article published elsewhere; or on issues of broad interest to the ocular therapeutic research community. A Letter should be concise, to the point (< 750 words), contain only text (no abstract, figures, tables), and be written in a continuous narrative style (no headings/subheadings). The Editor-in-Chief will be responsible for reviewing Letters to consider appropriateness for publication. If the Letter challenges some aspect of a prior publication, a complete citation of the publication in question is required. The authors of the publication in question will be given the opportunity to respond to the comments made (within 30 days), and the two Letters (if accepted) will be published sequentially in the same issue of the Journal.

    3. Review Articles: Timely review articles are periodically published in JOPT. Most published review articles are invited, however the Editor-in-Chief considers compelling unsolicited reviews. Prior to preparing a review article it is important to first contact the Editor-in-Chief with an abstract or outline to see if the review in question will be considered. While the length of a review will be governed by the scope of the topic covered, the suggested length is 5000 words.  Unlike original articles, the abstract of review articles are not formatted, but have 250 word limit.  All review articles are subject to full peer-review.

    Case Reports are no longer considered by JOPT.

    Manuscripts must be submitted through MANUSCRIPT CENTRAL. 


    If at any time during the online submission process you have a question or need help, click on the orange question mark icon titled Get Help Now in the upper right-hand corner of each page.  From here you will be able to:

    • "Find Answers” by searching ScholarOne’s database of solutions to previously resolved questions.
    • If you do not find the information you need, please contact authorservices@liebertpub.com


    A.  Permissions

         1. Written Permission
    The author must obtain, and submit to JOPT, written permission from the publisher (not the author or editor of the journal or book) whenever copyrighted material such as figures and tables will be included in the manuscript being submitted. The publication from which the figure or table is taken must also be included in the reference list. All written permissions must be submitted with the manuscript—they cannot be entered on proofs. 

         Written permission must be also be obtained from the author of any unpublished material cited from other laboratories, and should accompany the manuscript at submission.

    B.  Other Policies
         1. Declaration of Helsinki
             For research involving human subjects, JOPT requires that authors confirm adherence to the tenets of the Declaration of Helsinki in the METHODS section of their manuscripts.

          2. Use of Animals in Ophthalmic and Vision Research
      For research involving the use of animals, JOPT requires that the authors confirm adherence to the Association for Research in Vision and Ophthalmology (ARVO) statement for the Use of Animals in Ophthalmic and Vision Research in the METHODS section of their manuscripts.

    C.  Color Illustration Charges    
    Authors will be charged for the cost of color printing.  It is recommended that authors submit images in color only if they are prepared to pay the color charge.  Contact the Publisher for color costs.

    D.  Manuscript Preparation
     Please organize the manuscript as follows:
     • Title Page
     • Structured Abstract (250-word limit)
     • Text
     • Acknowledgments
     • References
     • Figure legends
     • Tables
     • Figures

     1. Title Page
    The title page should include the title of the article (limit 150 characters including spaces, etc.); author names, addresses, and institutions with superscripted numerals for identification; an asterisk to indicate the corresponding author; with mailing address, phone, fax, and e-mail address; proprietary interest (if any) for each author; a running title (limit 40 characters including spaces, etc.); word count for text (not including abstract, figure legends and references); and a list of up to 6 keywords.

    2. Structured Abstract (to be included in the manuscript file)
    The structured abstract (limit 250 words) should include the following: Purpose, Methods, Results, Conclusions.

    3. Text
    All manuscripts should be submitted double-spaced, with at least 1-inch margins all around (approximate length: 3,000 – 4,000 words).  Pages should be numbered consecutively; and include the first author’s name on each page. 

    At the end of the paper, provide the name and mailing address to whom reprint requests should be directed (include phone, fax, and e-mail address).

    The INTRODUCTION (without subheadings), should provide the research rationale and objectives, not an extensive literature review.

    The METHODS section should describe the experimental design, subjects used, and procedures followed. Provide sufficient detail to enable other scientists to duplicate the research. Use standard chemical or nonproprietary pharmaceutical nomenclature. In parentheses, identify equipment and chemical sources by brand name, company, city, and state, or country.

    If human subjects were involved in the study, confirm that:  (1) the research followed the tenets of the Declaration of Helsinki; (2) informed consent was obtained; (3) the research was approved by the institutional review board; and (4) power analysis was performed to justify the number of patients enrolled in the study.

    If experimental animals were used in the investigation, confirm that: (1) the research followed the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research; and (2) the research was approved by the institutional review board.

    The RESULTS should only describe data presented (clearly and concisely) with no discussion.  Cite all tables and figures with Arabic numbers in numerical order.

    The DISCUSSION should present the significance of the data (statistical, theoretical, etc.) in context of work described previously and their limitations. Do not reiterate the results.

    The DISCLOSURE STATEMENT should follow the Acknowledgments section, include a section entitled “Author Disclosure Statement.”

    In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision.

    Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at http://www.icmje.org/index.html#conflicts for further guidance.

    If no conflicts exist, the authors must state “No competing financial interests exist.”

    The ACKNOWLEDGMENTS should be limited to gifts in kind (antibodies, animals, specimens, etc.) and special assistance.

    The REFERENCES should be cited in the text, as superscripted numbers, in the order cited. If they also appear in  tables, or figures, use superscript numbers. Authors are responsible for the accuracy of the references. The reference list at the end of the manuscript should also be numbered in the order cited and conform to the following:

     • Reference to unpublished data (including material in preparation, or submitted, or personal communications) should be placed parenthetically in the text as: (1) author of the unpublished data or communication, and (2) year received or recorded.
                EXAMPLE: (Crosson, C.E. 2005)

     • Reference to an abstract should be placed parenthetically in the text as: (1) name of first author (if more than one author write “et al.” after the first author’s name and truncate the remaining names); (2) meeting where presented; (3) program or publication source (journal name in italics and abbreviated per Medline); (4) year; (5) volume number (if applicable); and (6) page or program number.
                EXAMPLE: (Yates, P.W. et al. Association for Research in Vision & Ophthalmology. Invest Ophthalmol Vis Sci, 2005; 44:E-Abstract 3686)

     • Reference to a journal article should include: (1) author(s) (if there are six or more authors, write “et al.” after the third author’s name and truncate the remaining names); (2) title (sentence case); (3) publication source (journal name in italics and abbreviated per Medline); (4) year; (5) volume number; and (6) inclusive page numbers.
                EXAMPLE: Shearer, T. Crosson, C.E. Activation of extracellular signal-regulated kinase in trabecular meshwork cells. Exp Eye Res. 2005; 73:25–35.

     • Reference to a book should include: (1) author(s) (if there are six or more authors, write “et al.” after the third author’s name and truncate the remaining names); (2) chapter title (sentence case); (3) editors (if chapter); (4) title of book (in italics); (6) city of publication; (7) publisher; (8) year; and (9) inclusive page numbers if chapter.
                EXAMPLE: (book): Wilson Jr., M.E., Trivedi, R.H., Pandy SK. Pediatric Cataract Surgery: Techniques, Complications and Management. Philadelphia: Lippincott Williams & Wilkins; 2005.
                EXAMPLE: (book chapter): Trivedi, R.H., Wilson Jr., M.E.  Cataract surgery in eyes treated for retinoblastoma. In: Wilson Jr., M.E., Trivedi, R.H., Pandy, S.K., eds. Pediatric Cataract Surgery: Techniques, Complications and Management.  Philadelphia: Lippincott Williams & Wilkins; 2005; p. 184–188.

    All FIGURE LEGENDS should appear in a list independent of the actual figures. 

    When naming your figure files, please label them with the last name of the first author, followed by a period (.), and then list the figure number. Ex: Smith. Fig1. Label figures and tables inside the files in addition to naming the file with the figure or table number. (ie. When figures or table files are opened, the figure or table number should appear inside the file.)

    All TABLES should be cited in the text, in numerical order using Arabic numbers. Each table must stand alone (i.e., contain all necessary information within the caption and legend), and the table itself must be understood independent of the text. Information that appears in the text should not be repeated in the tables, and tables should not contain data that can be given in the text in one or two sentences.

    All FIGURES should be cited in the text, in numerical order using Arabic numbers. If a figure contains multiple parts, it should be assembled onto one page (i.e., Figure 1A and 1B should not appear on separate pages).

    Please follow these guidelines for submitting artwork:

    • Do NOT embed art files into a Word or .pdf document.
    • Line illustrations should be submitted at 1200 dots per inch (dpi).
    • Halftones and color should be submitted at a minimum of 300 dpi. 
    • Save as either .tiff or .eps files.
    • Color art must be saved as CYMK—not as RGB.
    • Black and white art must be submitted as grayscale—not as RGB.
    • Do NOT submit PowerPoint, .pdf, Bitmap or Excel files.

    Please name your artwork files with the submitting authors name (i.e., Smith.Fig1.tif, Smith.Table2.tif etc.). Authors who do not follow these guidelines may have their submissions returned to them without being reviewed.


    Please upload individual files of all manuscript material — do NOT upload a single PDF file containing all text, figure, and table files of your paper. Once all individual files are uploaded on to Manuscript Central, the system will automatically create a single PDF proof for you and the peer-review process.   DO NOT upload a PDF of any text files.


    Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.

    You will be given directions on how to correct any files that are not useable.


    Converting Word or Excel files:  Perhaps the best and easiest way to convert Word or Excel files into a format which is suitable for print is to scan them using the guidelines below:

     • All files should be scanned at 100% size.
     • Make halftones 300 dpi and line art 1200 dpi.
     • Final color mode should be cmyk.
     • Save file as .tif or .eps.
    If you need directions on how to convert a PowerPoint slide to an acceptable format go to http://www.liebertpub.com/MEDIA/pdf/ppconvert.pdf


    E. Formatting Issues
     1. Manuscripts will be converted into an unalterable .pdf file at MANUSCRIPT CENTRAL and that .pdf file will be sent out for review. Files must be submitted (uploaded) in the following format:

    • Microsoft Word (.doc)

    2. Style
     JOPT uses the guidelines of style, terminology, measurement, and quantitation as set forth in the American Medical Association Manual of Style (9th ed., Baltimore, MD: Williams & Wilkins; 1998). 

     At first mention, define abbreviations and acronyms. 

     Use Système International (SI) measurements throughout the manuscript.


  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy

    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.


    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 




The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.